Single-Enantiomer Drugs
Authors:
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 43 (5) , 287-290
Abstract
Most new drugs are marketed as single enantiomers but many older agents are still available in racemic form. As these drugs reach the end of their patent life manufacturers become interested in marketing single enantiomer equivalents. This is called ‘chiral switching’ and it has been claimed that it will bring clinical benefits in terms of improved efficacy, more predictable pharmacokinetics or reduced toxicity. We reviewed the clinical evidence and prices for three recently marketed single enantiomer versions of widely used racemic drugs: escitalopram, esomeprazole and levosalbutamol. Claims of increased efficacy were based on comparisons of non-equivalent doses and any advantages seemed small and clinically unimportant. Prices of esomeprazole and levosalbutamol were higher than their racemic alternatives and we predict that these prices will remain high despite the market presence of generic versions of the racemates. Patent protection and a perception of superiority based on promotion rather than evidence will maintian price premiums for single enantiomer drugs that are not justified on the basis of clinical performance.Keywords
This publication has 18 references indexed in Scilit:
- Escitalopram: Superior to Citalopram or a Chiral Chimera?Psychotherapy and Psychosomatics, 2003
- The pharmaceutical industry as a medicines providerThe Lancet, 2002
- β2-Agonist EutomersAmerican Journal of Respiratory Medicine, 2002
- Stereoisomers in PsychiatryThe Primary Care Companion For CNS Disorders, 2002
- Impact of Stereoselectivity on the Pharmacokinetics and Pharmacodynamics of Antiarrhythmic DrugsClinical Pharmacokinetics, 2002
- Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterolJournal of Allergy and Clinical Immunology, 2001
- Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trialAlimentary Pharmacology & Therapeutics, 2000
- Enantiomers of bronchodilating β2 -adrenoceptor agonists: Is there a cause for concern?Journal of Allergy and Clinical Immunology, 1999
- Recent Advances in the Pharmacokinetics of Local AnaestheticsClinical Pharmacokinetics, 1999
- Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma☆☆☆★★★Journal of Allergy and Clinical Immunology, 1998